Featured Publications
Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric CancerSingle-Cell Atlas of Gastric Cancer Subtypes
Kumar V, Ramnarayanan K, Sundar R, Padmanabhan N, Srivastava S, Koiwa M, Yasuda T, Koh V, Huang K, Tay S, Ho S, Tan A, Ishimoto T, Kim G, Shabbir A, Chen Q, Zhang B, Xu S, Lam K, Lum H, Teh M, Yong W, So J, Tan P. Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric CancerSingle-Cell Atlas of Gastric Cancer Subtypes. Cancer Discovery 2022, 12: 670-691. PMID: 34642171, PMCID: PMC9394383, DOI: 10.1158/2159-8290.cd-21-0683.Peer-Reviewed Original ResearchConceptsPatient-derived organoidsPlasma cell proportionsGastric cancer subtypesLineage statePredictors of poor clinical prognosisCancer subtypesSingle-cell atlasCell proportionCancer-associated fibroblasts' subtypesCell populationsDiffuse-type tumorsPoor clinical prognosisIn vivo modelsComprehensive single-cell atlasPrimary tumorHistological subtypesRNA-sequencing cohortsTumor microenvironmentClinical stageClinical prognosisGastric malignancyTumor ecosystemGastric cancerCancer heterogeneityTumor
2019
DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial
Sundar R, Ng A, Zouridis H, Padmanabhan N, Sheng T, Zhang S, Lee M, Ooi W, Qamra A, Inam I, Hewitt L, So J, Koh V, Nankivell M, Langley R, Allum W, Cunningham D, Rozen S, Yong W, Grabsch H, Tan P. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal Of Cancer 2019, 123: 48-57. PMID: 31655359, DOI: 10.1016/j.ejca.2019.09.016.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCisplatinDNA MethylationEpigenesis, GeneticEsophageal NeoplasmsFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingPrognosisProportional Hazards ModelsRandomized Controlled Trials as TopicSurvival RateConceptsCS armNeoadjuvant chemotherapyOverall survivalOesophageal adenocarcinomaDNA methylation signaturesHistological subtypes of oesophageal cancerOesophageal cancerIndependent cohortPredictive of chemotherapy benefitSubtypes of oesophageal cancerIndependent cohort of patientsS armCox proportional hazards analysisResectable oesophageal cancerCohort of patientsPredictive of benefitMethylation signaturesDNA methylationPredictive of survivalProportional hazards analysisChemotherapy benefitHistological subtypesMetagene signatureRandomised patientsDNA methylation status